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TECHNICAL NOTE
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Can murine diabetic nephropathy be separated from superim-
posed acute renal failure?
Background.Streptozotocin (STZ) is commonly used to in-
duce diabetes in experimental animal models, but not without
accompanying cytotoxic effects. This study was undertaken to
(1) determine an optimal dose and administration route of STZ
to induce diabetic nephropathy in wild-type mice but without
the concurrent acute renal injury resulting from cytotoxic ef-
fects of STZ and (2) evaluate the pattern of tubular injury and
interstitial inflammation in this model.
Methods. Male Balb/c mice received either (1) STZ (225 mg/
kg by intraperitoneal injection.); or (2) two doses of STZ 5 days
apart (150 mg/150 mg/kg; 75 mg/150 mg/kg; 75 mg/75 mg/kg; and
100 mg/100 mg/kg by intravenous injection). Another strain of
mice, C57BL/6J, also received STZ (200 mg/kg intravenously or
intraperitoneally). Renal function and histology were examined
at weeks 1, 2, 4, and 8 after induction of diabetes. In initial
optimization studies, animals were sacrificed at week 1 or week
2 and histology examined for acute renal injury.
Results. Following a single intraperitoneal injection of 225
mg/kg of STZ, only two thirds of animals developed hyper-
glycemia, yet the model was associated with focal areas of acute
tubular necrosis (ATN) at week 2. ATN was also observed in
C57BL/6J mice given a single intravenous or intraperitoneal
dose of STZ (200 mg/kg), at week 2 post-diabetes. At an op-
timal diabetogenic dose and route (75 mg/150 mg/kg by intra-
venous injection 5 days apart), all mice developed diabetes and
no ATN was observed histologically. However, even with this
regimen, glomerular filtration rate (GFR) was significantly im-
paired from week 2. This regimen was accompanied by pro-
gressive histologic changes, including tubular and glomerular
hypertrophy, mesangial area expansion, as well as interstitial
macrophage, CD4+ and CD8+ T-cell accumulation.
Conclusion. By careful optimization of STZ dose, a stable
and reproducible diabetic murine model was established. How-
ever, even in this optimized model, renal functional impairment
was observed. The frequency of ATN and functional impair-
ment casts doubt on conclusions about experimental diabetic
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nephropathy drawn from reports in which ATN has not been
excluded rigorously.
Streptozotocin (STZ)-induced diabetes is a commonly
used experimental model in rats and mice to investigate
the pathogenesis of human diabetic nephropathy. Mice
are more resistant to the diabetogenic effect of STZ than
rats. In mice, other investigators have used either, in ex-
cess of two consecutive daily intraperitoneal injections of
200 mg/kg [1]; a single intravenous injection of 300 mg/kg
[2]; or intraperitoneal administration at lower doses of
50 mg/kg for 5 consecutive days [3].The possible super-
imposition of acute tubular necrosis (ATN) was not con-
sidered in these studies [1–3], and as a consequence the
interpretation of findings is confounded. The aim of this
study was therefore to identify a nonnephrotoxic dose of
STZ in wild-type mice and then determine characteris-
tics of renal interstitial inflammation and tubular injury
in this optimized model.
METHODS
Animals
Inbred male BALB/c and C57BL/6J mice, 6 to 8 weeks
old and weighing 20 to 25 g (Animal Resource Center,
Perth, Australia) were housed at the Animal Care Facility,
Westmead Hospital, and allowed free access to standard
food pellets and water. All experimental protocols were
approved by the Animal Care and Ethics Committee,
Westmead Hospital.
Experimental design
In the initial study, animals (regimen A) received a
single intraperitoneal dose (225 mg/kg) of STZ (Sigma
Chemical Co., St. Louis, MO, USA) (S-0130) dissolved
in sterile saline. Lower doses of STZ were examined
when this regimen was found to cause ATN. In a sec-
ond study, STZ was administered intravenously twice, 5
days apart. The doses used were (regimen B) 75 mg/kg/
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150 mg/kg; (regimen C) 150 mg/kg/150 mg/kg; (regimen
D) 100 mg/kg/100 mg/kg; or (regimen E) 75 mg/kg/75
mg/kg. In a supplementary study, C57BL/6J mice re-
ceived a single intravenous(regimen F) or intraperitoneal
(regimen G) dose (200 mg/kg) of STZ. All animals were
nonfasted at the time of STZ administration.
Following STZ, morning blood glucose was measured
daily by tail-vein sampling using a glucometer (Roche,
Basel, Switzerland). Only animals with two consecutive
morning nonfasting blood glucose levels of >16 mmol/L
were included in the study. Long-acting insulin (Humulin
Lente, Aza Research, Castle Hill, NSW, Australia) was
given subcutaneously to prevent weight loss and maintain
hyperglycemia (blood glucose levels between 15 and 30
mmol/L) or normoglycemia (blood glucose levels <10
mmol/L). Diabetic and control animals were sacrificed
under anesthesia at time points detailed under respective
figure/table legends.
Renal function
Animals were placed in metabolic cages for 16 hours
with food and water, a day prior to sacrifice. Total urinary
protein was determined using the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). Urinary
glucose was measured using a glucometer (Roche), and
diluted where necessary to fit within the linearity range of
the glucometer. Urinary creatinine was measured by the
Vitros Crea slide method, as the high glucose content in
urine of diabetic animals interfered with measurements
using the Jaffe´ method [4]. Blood samples for serum cre-
atinine were obtained at the time of sacrifice by cardiac
puncture, and measured with a commercial kit (Sigma
Chemical Co.) (555-A) using an improved colorimetric
assay based on the Jaffe´ method [5, 6]. Creatinine clear-
ance was calculated as creatinine excreted in the urine
(16-hour period) divided by the creatinine concentration
in serum, and the results were expressed as mL/min.
Histology and morphometric analysis
At the time of sacrifice, after blood samples had been
taken, the animals were exsanguinated and kidney sam-
ples were removed and weighed. Coronal slices were
immersion-fixed in 10% neutral-buffered formalin for
24 hours, then dehydrated in graded alcohols, and embed-
ded in paraffin. Sections, 4 lm in thickness, were stained
with periodic acid-Schiff (PAS). A comparison of histo-
logic markers of tissue injury was made among animal
subgroups using an image analysis system (Optimas 5.23)
(Optimas Corporation, Seattle, WA, USA) as described
previously [7]. Mean values were calculated from each of
20 glomeruli, 50 tubules, or 10 random cortical regions
per section.
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Fig. 1. Comparison of histologic changes in periodic acid-Schiff (PAS)–stained renal cortical sections from BALB/c mice (A to D and F) and
C57BL/6J mice (E). (A) Without any injection. (B to D) with a single high dose of streptozotocin (STZ) (225 mg/kg intraperitoneally, (F) with two
low doses of STZ (75 mg, 150 mg/kg intravenously, and (E) with a single high dose of STZ (200 mg/kg) intravenously. Diabetic animals maintained
at normoglycemia were sacrificed at week 2 (D), while those maintained at hyperglycemia were sacrificed at week 1 (B) and week 2 (C, E, and
F). The arrowed tubules in (B to E) show denudation of the epithelial cells consistent with acute tubular necrosis (ATN). Arrowheads (F) denote
interstitial cell infiltrates (magnification 400×).
Immunohistochemistry
Coronal slices of kidneys were embedded in 22-
oxacalcitriol (OCT) compound (Tissue-Tek, Sakura
Finetek, Torrance, CA, USA), frozen in liquid nitro-
gen and then stored at −70◦C. Frozen sections, 5 lm
in thickness, were fixed with acetone at 4◦C for 15
minutes. Sections were incubated with 5% normal rab-
bit serum followed by antibodies against macrophages
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Table 2. Comparison of functional and histologic markers in study where a single high dose of streptozotocin (STZ) (225 mg/kg) was
administered intraperitoneally
Control Week 2 post-STZ Week 4 post-STZ Week 6 post-STZ
Serum creatinine lmol/L 18.0 ± 4.9 29.3 ± 2.9a 18.6 ± 1.2 37.4 ± 7.6a
Glomerular tuft area lm2 2373 ± 43 2308 ± 47 2471 ± 46 2666 ± 44a
Glomerulosclerosis index (%PAS material in tuft) 28.2 ± 0.6 27.8 ± 0.7 30.5 ± 0.7 29.1 ± 0.7
Proximal tubular cell height lm 16.3 ± 2.6 NA NA 15.3 ± 2.6b
Proximal tubular diameter lm 32.7 ± 0.7 NA NA 31.4 ± 0.6
Interstitial area (% of cortex) 13.9 ± 4.7 18.3 ± 3.5a 13.1 ± 3.4 16.6 ± 5.6a
Tubular cell ultrastructure was not assessed (NA) at 2 and 4 weeks after streptozotocin (STZ) because of the presence of acute tubular necrosis (ATN).
All data expressed as mean ± SD.
aP ≤ 0.01 when compared to control group.
bP ≤ 0.05 when compared to control group.
(rat antimouse F4/80 antigen) (Serotec)(MCA-497), CD4
(purified antimouse CD4) (L3T4)(RM4-5) (Pharmigen)
(553043), and CD8 (purified antimouse CD8a) (Ly-2)
(53-6.7) (Pharmigen) (553027) for 60 minutes at
room temperature; biotinylated rabbit anti-IgG (1:200);
and then avidin-biotin-horseradish peroxidase complex
(30 minutes each at room temperature). The reaction
was visualized by 3,3-diaminobenzidine tetrahydrochlo-
ride (DAB).
The number of macrophages, CD4+ and CD8+ cells
was quantitated in 10 nonoverlapping cortical fields
(×400, measuring 0.075 mm2 each). Using image analysis
of cells as described above, the mean number of posi-
tive cells per interstitial field was calculated for each sec-
tion and expressed as cells per mm2. Similarly, the num-
ber of positive cells per glomerulus was counted (×400),
and the mean for 20 randomly selected glomeruli was
determined.
Statistical analysis
The results are expressed as mean ± standard de-
viation. Statistical comparisons between animal groups
were performed using a computer-based statistical pack-
age (SPSS version 8.0, Chicago, IL, USA). A one-way
analysis of variance (ANOVA) was used and subgroups
were then compared by post hoc analysis using the least
squares method. A P value of < 0.05 was considered to
represent statistical significance.
RESULTS
Only two-thirds of 18 BALB/c mice injected with
225 mg/kg (intraperitoneal injection) developed diabetes
(blood glucose le vel >16 mmol/L) by day 7 (Table 1). At
this dose, focal areas of ATN with tubular vacuolization
were noted at week 1 and 2 in diabetic mice (Fig. 1B and
C), and were associated with interstitial expansion and
a rise in serum creatinine (Table 2). These changes were
absent at week 4 but were seen again at week 6. Normal-
ization of bblood glucose level (<10 mmol/L) up to the
week 2 time point did not prevent ATN (Fig. 1D). The
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Fig. 2. Urinary glucose, lmol/16 hours (A), serum creatinine, lmol/L
(B), creatinine clearance, mL/minute (C), for normal and diabetic
BALB/c mice (regimen B, 75 mg, 150 mg/kg streptozocin (STZ) in-
travenously sacrificed at weeks (w) 1, 2, 4, and 8 post-STZ. Values are
expressed as mean ± SD. ∗P <.05; ∗∗P < 0.001 when compared to nor-
mal animals.
nephrotoxicity of STZ was not only confined to BALB/c
mice. C57BL/6J mice injected with a dosage commonly
used to induce diabetes in the study of diabetic nephropa-
thy (≥200 mg/kg intravenously or intraperitoneally)
exhibited morphologic evidence of ATN at week 2 (Fig.
1E), with a milder degree at week 1.
In contrast, two lower doses of STZ injected intra-
venously through the tail vein of BALB/c mice [75
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Fig. 3. Comparison of histologic changes in periodic acid-Schiff
(PAS)–stained renal sections from BALB/c mice (A) without any in-
jection, (B and C) injected with two low doses of streptozotocin (STZ)
(75 mg, 150 mg/kg intravenously). Diabetic mice were maintained at
hyperglycemia. Arrows denote interstitial cell infiltrates at week 2 (B)
and glomerulosclerosis at week 8 (C) (magnification 400×).
mg/kg/150 mg/kg or 150 mg/kg/150 mg/kg (5 days after
the first injection)], produced a more consistent model
of diabetes, where all animals developed diabetes (Table
1) (Fig. 2A) Lower doses of 100 mg/kg/100 mg/kg or 75
mg/kg/75 mg/kg did not result in diabetes even up to 2
weeks later. There was no histologic evidence of ATN
in the two-injection model (Fig. 1F). However, diabetic
animals (regimen B, 75 mg, 150 mg/kg) developed pro-
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Fig. 4. Morphometric analysis of normal and diabetic BALB/c mice
sacrificed at weeks (w) 1, 2, 4 and 8 after induction of diabetes with 75
mg, 150 mg/kg streptozotocin (STZ). Diabetic mice were maintained
at hyperglycemia prior to sacrifice. (A) Cortical tubular cell height, lm.
(B) Glomerular area, lm2. (C) Glomerulosclerosis index [% of periodic
acid-Schiff (PAS) material in tuft]. (D) Interstitial area (% of cortex).
Values are expressed as mean ± SD. ∗P < 0.05; ∗∗P < 0.005.
gressive renal functional impairment from week 2, and
this persisted until week 8 (Fig. 2B).
Proteinuria did not increase in diabetic animals ex-
pressed either as an absolute value (week 1, 6 ± 2; week
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Fig. 5. Stained renal cryosections from BALB/c mice, sacrificed at week 2, (A, C, and E) without any injection; (B, D, and F) with two low doses of
streptozotocin (STZ) (75 mg, 150 mg/kg intravenously) and maintained at hyperglycemia. (A and B) Stained for CD4. (C and D) Stained for CD8.
(E and F) Stained for macrophage. Arrows denote respective cell surface markers (magnification 400×).
2, 3 ± 1; week 4, 7 ± 3; and week 8, 6 ± 3 vs. control, 10 ±
6 mg/16 hours) (P > 0.1), or as urinary protein-creatinine
ratio (week 1, 3.59 ± 0.94; week 2, 3.15 ± 1.23; week 4,
3.65 ± 1.89; and week 8, 4.45 ± 1.55 vs. control, 3.80 ±
1.42 mg/lmol) (P > 0.5).
Diabetic animals developed progressive histological
changes (Fig. 3), including an increase in tubular cell
height (Fig. 4A), glomerular hypertrophy (Fig. 4B),
mesangial area expansion and increase in glomeruloscle-
rosis index (Fig. 4C), and a reduction in interstitial area
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Table 3. Comparison of interstitial inflammatory cell numbers between normal and diabetic BALB/c mice [diabetes was induced with 75 mg, 150
mg/kg streptozotocin (STZ) intravenous injection]
Interstitial inflammatory cell types Week 1 Week 2 Week 4 Week 8
(no. of cells/field) Normal post-STZ post-STZ post-STZ post-STZ
CD4 3.3 ± 0.3 6.7 ± 2.3 16.1 ± 2.9a 10.1 ± 2.8a 10.4 ± 2.6a
CD8 1.8 ± 0.9 3.8 ± 1.2 18.3 ± 2.9a 10.3 ± 1.8a 9.8 ± 2.0a
Macrophage 8.7 ± 1.5 10.2 ± 2.9 53.0 ± 7.5a 38.4 ± 4.0a 23.2 ± 1.8a
aP ≤ 0.001 vs. normal controls.
at weeks 1 and 2 (Fig. 4D). Despite the reduction in in-
terstitial area, interstitial CD4+ and CD8+ T-cell and
macrophage infiltration was detected as early as 1 to
2 weeks post-STZ injection (Fig. 5B, D, and F, respec-
tively). Cell numbers reached a peak by week 2 (P <
0.0001 vs. control, for all three cell types), but decreased
dramatically in later stages (Table 3). Glomerular CD4+,
CD8+ T cell and macrophage numbers were not in-
creased in STZ-mice.
DISCUSSION
The results of the present study demonstrate that, in
male BALB/c mice, (1) a more stable and reproducible di-
abetic murine model could be established by intravenous,
rather than intraperitoneal injection of streptozotocin;
(2) the optimal diabetogenic dose of STZ that did not
cause histologically evident ATN was 75 mg STZ/kg given
intravenously, with a second dose of 150 mg/kg adminis-
tered 5 days later; and (3) even at these apparently non-
nephrotoxic doses, renal dysfunction was evident. Thus
it is not possible to determine if the accompanying inter-
stitial infiltration of lymphocytes and macrophages was a
consequence of diabetes or superimposed ATN.
There are numerous regimens to induce STZ-induced
diabetes in mice. Consistent with previous results we
found that administration of STZ by the intraperitoneal
route was a less reliable method of induction [3]. How-
ever, of greater importance, we found that a single high-
dose of STZ intraperitoneally caused focal areas of ATN.
Therefore, we examined lower doses of STZ and found
that either 75 mg, 150 mg/kg and 150 mg, 150 mg/kg
given intravenously 5 days apart, produced diabetes in
all the mice without structural evidence of ATN, whereas
lower doses did not induce diabetes. However, with opti-
mally diabetogenic regimen, ATN could not be excluded
as glomerular filtration rate (GFR) was significantly
reduced. Utilization of STZ-diabetic model without ATN
is important because superimposed ATN would con-
found the interpretation of results.
The occurrence of ATN is not specific to BALB/c mice
when a nonoptimized dose of STZ is used to induce di-
abetes, neither is it as a result of hyperglycemia. In our
supplementary study, C57BL/6J mice injected with a sin-
gle high dose of STZ (200 mg/kg intravenous or intraperi-
toneal) also developed ATN at 1 to 2 weeks. Normalizing
blood glucose level of diabetic BALB/c mice after STZ
induction (225 mg/kg) did not alleviate ATN. Previous
studies in mice [3] examined renal histology 8 weeks after
STZ treatment, and did not take into account potential
effects of ATN. There are numerous published studies ex-
amining a whole range of issues in STZ diabetic mice and
other STZ diabetic rodent models. Rat islet cells are much
more sensitive to the toxic effects of STZ so that much
lower doses of STZ can be used (40 mg to 60 mg/kg). How-
ever optimal nonnephrotoxic STZ doses that do not cause
acute renal injury histologically have not been assessed
rigorously in rats either. In none of these has ATN been
examined for adequately and so the conclusions must be
questioned [8–14]. For example, renal bone morphogenic
protein-7 (BMP-7) was reported to be decreased in rats
with STZ diabetes [14]. Similar observations have been
made in the setting of acute renal failure [15], and so
it is quite possible that the reported changes in diabetic
mice should be attributed to superimposed ATN rather
than diabetes per se. The same argument applies to other
observations in STZ-diabetic mice [8–13] where super-
imposed ATN has not been excluded rigorously.
At the optimal diabetogenic dose of STZ, diabetic an-
imals developed progressive histologic changes typical
of diabetic nephropathy, including tubular hypertrophy,
glomerular hypertrophy, and mesangial area expansion.
This was accompanied by an early interstitial inflamma-
tory cell infiltration by macrophages and T lymphocytes,
similar to human diabetic nephropathy as well as other
murine models of chronic renal disease [16, 17]. The role
of tubulointerstitial macrophages and T cells in this and
other models of diabetic nephropathy remain unclear, as
does their relationship to superimposed ATN.
CONCLUSION
Our study shows that even with careful optimization
of the STZ dose, superimposed ATN cannot be sepa-
rated from diabetic nephropathy. The possible effect of
superimposed ATN must be considered when drawing
conclusions from the model of STZ diabetes.
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